Trial Profile

Observational Program for Evaluation of Ribomustin Use in the First Line Therapy of Chronic Lymphocytic Leukemia

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Jul 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bendamustine (Primary) ; Rituximab
Indications Chronic lymphocytic leukaemia
Focus Therapeutic Use
Sponsors Astellas Pharma

Most Recent Events

25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
27 Jun 2016 Status changed from active, no longer recruiting to completed.
19 Oct 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com